T-cell and Antibody-mediated rejection after organ transplantation in the post-COVID-19 era – diagnosis, immunological risk evaluation and therapy

While organ transplantation programs around the world are coping with the grave consequences of the COVID-19 pandemic, immunological complications after transplantation still represent an ever growing medical and socio-economic problem. Antibody-mediated rejection remains the main immunological cause of kidney graft failure.

The Research Topic will shed light on the growing application of new techniques and approaches (e.g., next-generation sequencing, detection of donor-derived DNA, the molecular microscope, HLA epitope matching) to improve rejection diagnosis and immunological risk evaluation. In addition, evidence will be provided on the new therapeutic advances in the management of T-cell and antibody-mediated rejection. The pathological features and clinical diagnosis of rejection in various transplanted organs significantly differ, so, we welcome experts from those areas to give contributions from their fields.

We welcome the submission of Review, Original Research, Opinion, and Perspective articles covering, but not limited to, the following aspects:

1. Application of next-generation sequencing and HLA epitope matching in organ transplantation.

2. The use of Molecular microscope, donor-derived DNA, and other novel methods for diagnosis and risk evaluation of the development of T-cell and antibody-mediated rejection

3. The role of non-HLA immunity in kidney, heart, and lung transplant recipients

4. The molecular mechanisms of transplantation tolerance – results of multicenter studies, perspectives, and future developments

5. The influence of COVID-19 on organ transplantation – rejection risk, organ allocation, and others